RxDoctor Payments DataLook up a doctor →

Kari Joyner

Adult Health · McBee, SCNPI 1225454432

Payments from drug & device makers

$7,419in general payments, 2019–2025

Across 398 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$849
  • Lilly USA, LLC$523
  • Pfizer$492
  • Amgen$470
  • Abbott$307
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,32999%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,419 in reported general payments places this provider in the 90th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$100,229
Medicare patients
374
Services billed
2,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$55,690
OzempicSemaglutide23$35,472
EliquisApixaban30$23,835
XareltoRivaroxaban16$19,657
GlyxambiEmpagliflozin/Linagliptin19$19,463
TrulicityDulaglutide20$18,476
JanuviaSitagliptin Phosphate22$18,461
LinzessLinaclotide19$16,027
JardianceEmpagliflozin16$13,759
Xigduo XrDapaglifloz Propaned/Metformin12$4,219
Levothyroxine Sodium148$2,536
Duloxetine Hcl46$2,400
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$2,111
Omeprazole131$1,987
Atorvastatin Calcium141$1,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$523$74,16649 claims
Novo NordiskOzempic$849$35,47223 claims
Boehringer IngelheimGlyxambi, Jardiance$136$33,22135 claims
PfizerEliquis$492$23,83530 claims
Johnson & JohnsonXarelto$26$19,65716 claims
MerckJanuvia$130$18,46122 claims
AbbVieLinzess, Synthroid$1,571$17,60250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 adult health providers in South Carolina.

Other adult health in McBee

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →